Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning

NCT04009967 | Active Not Recruiting Phase 2 FDA Drug

• 1 other identifier: 3475-910/OTSP-57
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Various approaches are currently being developed for prostate cancer immunotherapy. However, a major challenge facing the development of cancer immunotherapy is the identification of tumors that would best respond to this type of treatment. Different studies suggest that prostate cancer more likely to progress are more infiltrated by exhausted T cells expressing the cell surface protein PD1 (Programmed cell death 1). Therefore, there is a strong rationale for selecting patients at higher risk of progression for testing the efficacy of anti-PD1 therapy. High glucose metabolism as detected by fludeoxyglucose F18 (FDG)-positron emission tomography (PET) (18FDG-PET) imagery is an innovative biological biomarker-based method to identify patients at higher risk of recurrence and early failure to hormonotherapy. Recent study demonstrated that high intra-prostatic 18-FDG-uptake was associated with higher Gleason grades. Therefore the one third of Gleason ≥ 8 prostate cancer patients with higher 18FDG uptake would be ideal candidates for early immunotherapy treatments based on anti-PD-1 such as pembrolizumab. The study aimed to identify biomarkers predictive the response to Pembrolizumab given prior to radical prostatectomy in participants with primary prostate cancer at high risk of progression.

Conditions

Prostate Cancer

Keywords

Prostate Cancer; Pembrolizumab; 18FDG-PET Scanning

Outcome Measures

Primary Outcomes (3)

• The antitumor activity of pembrolizumab assessed as the tumor response rate based on the change in tumor volume as measured by 18FDG-PET

  The change in tumor volume will be assessed by change in tumor volume from baseline after 3 cycles of pembrolizumab treatment

  Through study completion, an average of 1 year

• Mean difference change in proliferative index in prostate cancer patients between patients treated with pembrolizumab and the control cohort

  Proliferative index is measured by Ki67/apoptosis rate

  Through study completion, an average of 1 year

• Immune cell infiltration and immune checkpoint expression

  Compare large panel of ICP (Immune CheckPoints) ligand expression between patients treated by pembrolizumab and cohort control by imaging mass cytometry

  Through study completion, an average of 1 year

Secondary Outcomes (5)

• One year PSA (Prostate Specific Antigen) failure rate

  At the end of study completion, an average of 3 years

• Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0

  Through study completion, an average of 2 years

• Number of participants with decrease in SUV uptake after 3 cycles of pembrolizumab

  Through study completion, an average of 2 years

• Assess a possible correlation between deficient mismatched repair (dMMR) and microsatellite instability-high (MSI-H) and response to pembrolizumab.

  At the end of study completion, an average of 3 years

• Assess the expression of a series of cytokines and eicosanoids

  At the end of study completion, an average of 3 years

Study Arms (1)

Prostate Cancer

EXPERIMENTAL

Participants will receive 3 cycles of pembrolizumab regardless of PD-L1 status. After completion of the second cycle of pembrolizumab treatment, and just before the third injection of pembrolizumab an 18FDG-PET/CT scan will be performed to assess a potential metabolic response. Then between 2 to 4 weeks after the third treatment, subjects will undergo radical prostatectomy. Subjects will be followed every 3 months during the first year post-surgery and according to physician decision during the following years.

Drug: Pembrolizumab

Interventions

Pembrolizumab DRUG

Pembrolizumab 200 mg every three weeks for 3 cycles only

Also known as: Keytruda

Prostate Cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male Age≥ 18 years old
• Non-metastatic prostate cancer with histologically confirmed Gleason sum ≥8
• Eligible for radical prostatectomy with a delay of 6 to 9 weeks
• Intraprostatic maximum standardized uptake value (SUVmax) ≥4 at 18-FDG-PET/CT exam.
• Not be castrated or under androgen deprivation therapy
• Not have received prior neo adjuvant hormonotherapy.
• Provided archival formalin-fixed, paraffin embedded tumor biopsy of the prostate tumor lesion not previously irradiated
• Performance status of Eastern Cooperative Oncology Group 0 to 1
• Adequate organ function

You may not qualify if:

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4 (Cytotoxic T-lymphocyte-Associated Protein 4), OX-40, CD137).
• Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation.
• Has received prior radiotherapy to the prostate or other organs within 2 weeks of start of study treatment.
• Has received a live vaccine within 30 days prior to the first dose of study drug.
• Is participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
• Other primary cancer within 3 years
• Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
• Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
• Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
• Has an active infection requiring systemic therapy.
• Has a known history of Human Immunodeficiency Virus (HIV).
• Has a known history of Hepatitis B or known active Hepatitis C virus infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Sponsors & Collaborators

• CHU de Quebec-Universite Laval: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

CHU de Québec-Université Laval

Québec, Canada

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

pembrolizumab

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Yves Fradet, MD

  CHU de Québec-Université Laval

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 17, 2019
• First Posted: July 8, 2019
• Study Start: January 10, 2020
• Primary Completion: September 1, 2024
• Study Completion: March 30, 2025
• Last Updated: January 13, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)